Cargando…

The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects

BACKGROUND: The new STHLM3 test, combining protein markers, genetic markers, and clinical data to assess a man’s prostate cancer (PCa) risk, has been investigated in Sweden within the frame of the STHLM3 trial. OBJECTIVE: To assess whether the STHLM3 test influences men’s worry level, PCa knowledge,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koitsalu, Marie, Eklund, Martin, Adolfsson, Jan, Sprangers, Mirjam A.G., Grönberg, Henrik, Brandberg, Yvonne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Prostate Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317863/ https://www.ncbi.nlm.nih.gov/pubmed/34337495 http://dx.doi.org/10.1016/j.euros.2020.12.010

Ejemplares similares

Predictors of participation in risk-based prostate cancer screening
por: Koitsalu, Marie, et al.
Publicado: (2018)

Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms
por: Nordström, Tobias, et al.
Publicado: (2021)

External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort
por: Chandra Engel, Jan, et al.
Publicado: (2022)

Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening
por: Andersson, Joel, et al.
Publicado: (2022)

Effects of pre-notification, invitation length, questionnaire length and reminder on participation rate: a quasi-randomised controlled trial
por: Koitsalu, Marie, et al.
Publicado: (2018)

A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study
por: Waldén, Mauritz, et al.
Publicado: (2022)

Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
por: Guldvik, Ingrid J., et al.
Publicado: (2020)

Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative
por: Remmers, Sebastiaan, et al.
Publicado: (2022)

Prostate Cancer Tumor Volume and Genomic Risk
por: Ramaswamy, Ashwin, et al.
Publicado: (2023)

Characteristics of Patients in SPCG-15—A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer
por: Gongora, Magdalena, et al.
Publicado: (2022)

Active Surveillance—Is It Feasible for Intermediate-risk Localised Prostate Cancer?
por: Mukherjee, Subhabrata, et al.
Publicado: (2021)

The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator
por: Parekh, Sneha, et al.
Publicado: (2022)

A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy
por: Kelly, Brian D., et al.
Publicado: (2023)

Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital
por: Kan, Carolyn K., et al.
Publicado: (2017)

Impact of Health-related Quality of Life and Prediagnosis Risk of Major Depressive Disorder on Treatment Choice in Low- and Intermediate-Risk Prostate Cancer
por: Riskin-Jones, Hannah, et al.
Publicado: (2020)

Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study
por: Norris, Joseph M., et al.
Publicado: (2021)

Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study
por: Robertson, Nicola L., et al.
Publicado: (2014)

Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer
por: Wagaskar, Vinayak G., et al.
Publicado: (2021)

Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths
por: Lycken, Magdalena, et al.
Publicado: (2022)

Clinical Application of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Score for Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer
por: Aerts, Jan, et al.
Publicado: (2023)

Reliability of Ancestry-specific Prostate Cancer Genetic Risk Score in Four Racial and Ethnic Populations
por: Shi, Zhuqing, et al.
Publicado: (2022)

Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study
por: Tosoian, Jeffrey J., et al.
Publicado: (2021)

Comparative Survival Outcomes of High-risk Prostate Cancer Treated with Radical Prostatectomy or Definitive Radiotherapy Regimens
por: Aas, Kirsti, et al.
Publicado: (2021)

Profiling of Skeletal Muscle and Adipose Tissue Depots in Men with Advanced Prostate Cancer Receiving Different Forms of Androgen Deprivation Therapy
por: Blow, Tahj A., et al.
Publicado: (2023)

Comparison of Survival Outcomes and Risk Factors Between Ductal Carcinoma of the Prostate and Acinar Adenocarcinoma of the Prostate: A Population-based Propensity Score–matching Study
por: Wei, Yongbao, et al.
Publicado: (2022)

Prospective Implementation and Early Outcomes of a Risk-stratified Prostate Cancer Active Surveillance Follow-up Protocol
por: Thankapannair, Vineetha, et al.
Publicado: (2023)

Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data
por: Remmers, Sebastiaan, et al.
Publicado: (2021)

Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer
por: Fischer-Valuck, Benjamin W., et al.
Publicado: (2022)

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
por: Autio, Karen A., et al.
Publicado: (2021)

Which Type of Exercise During Radiation Therapy Is Optimal to Improve Fatigue and Quality of Life in Men with Prostate Cancer? A Bayesian Network Analysis
por: Xiong, Xingyu, et al.
Publicado: (2022)

Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
por: Guldvik, Ingrid Jenny, et al.
Publicado: (2022)

Clinical Value of a Routine Urine Culture Prior to Transrectal Prostate Biopsy
por: Örtegren, Joakim, et al.
Publicado: (2022)

Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: A propensity score-matched analysis
por: Markovina, Stephanie, et al.
Publicado: (2017)

Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
por: Olivier, Jonathan, et al.
Publicado: (2022)

A Multicenter Phase 2 Study of Ultrahypofractionated Stereotactic Boost After External Beam Radiotherapy in Intermediate-risk Prostate Carcinoma: A Very Long-term Analysis of the CKNO-PRO Trial
por: Pasquier, David, et al.
Publicado: (2023)

Red Blood Cell Distribution Width Is Associated with All-cause Mortality but Not Adverse Cancer-specific Outcomes in Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy: Findings Based on a Multicenter Shared Equal Access Regional Cancer Hospital Registry
por: Orabi, Hazem, et al.
Publicado: (2022)

Risk of Recurrent Disease 6 Years After Open or Robotic-assisted Radical Prostatectomy in the Prospective Controlled Trial LAPPRO
por: Nyberg, Martin, et al.
Publicado: (2020)

Risk Estimation of Metastatic Recurrence After Prostatectomy: A Model Using Preoperative Magnetic Resonance Imaging and Targeted Biopsy
por: Bommelaere, Thomas, et al.
Publicado: (2022)

Magnetic Resonance Imaging–targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer
por: Alkema, Nicolette G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pl5pgs6jm3r6n2kusvpkk88cas